510(k) Report

510(k) · Cleared

Cleared

Visiquant Anti-Nuclear Antibody Test System

K022800510(k) TraditionalCleared Nov 25, 200294-day reviewClass II21 CFR 866.5100

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Hyperion, Inc. · DHN Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control

Cleared on Nov 25, 2002 as substantially equivalent to K013213 (Hyperion, Inc., 2002) after a 94-day review. Its family tree reaches back 2 generations to 1987.

Decided
Nov 25, 2002
Review
94 days
Class
Class II
Product code
DHN
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K872845 (1987). No later device cites it as a predicate yet.

  1. Root · 2 generations backK872845 Bion Antinuclear Antibody (Ana)Test Kit/Contr SerumBion Ent., Ltd. · 1987
  2. 1 generation backK013213 Hyperion Visiquant Ana Test KitHyperion, Inc. · 2002
  3. This deviceK022800 Visiquant Anti-Nuclear Antibody Test SystemHyperion, Inc. · 2002
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K872845Bion Antinuclear Antibody (Ana)Test Kit/Contr SerumBion Ent., Ltd.1987—
−1K013213Hyperion Visiquant Ana Test KitHyperion, Inc.2002—
0 (this device)K022800Visiquant Anti-Nuclear Antibody Test SystemHyperion, Inc.2002—
FIG. 1 — Lineage of K022800, 1987–2002Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DHN? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K013213Hyperion Visiquant Ana Test Kit
Summary page 1
…TMANA System is substantially equivalent to the VisiQuantTMANA Test Kit using a specially equipped fluorescent microscope, previously cleared under Document Control No., K013213, on 6/04/2002. The proposed and the predicate device are both in-vitro diagnostic products, intended for the visual determination…
Hyperion, Inc.2002—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 15 years and passes through 2 companies; a new generation was cleared every 14.8 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All DHN devices

DHN Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · DHN

1in 2022

2007: 12012: 12014: 12015: 22016: 22018: 12022: 1
2007high 2 (2015) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DHN

Too few DHN 510(k)s in any year since 2007 to give a median.

Recalls per year · DHN

1in 2011

2008: 22010: 12011: 1
2007high 2 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DHN

No MAUDE report names DHN since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20080—20
20090—00
20100—10
20110—10
20121—00
20130—00
20141—00
20152—00
20162—00
20170—00
20181—00
20190—00
20200—00
20210—00
20221—00
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

The VisiQuant™ Anti-Nuclear Antibody Test System is intended for the visual determination of anti-nuclear antibodies (ANA’s) immunofluorescence pattern(s) and the semi-quantitative measurement of ANA’s in human serum with a single dilution as an aid in the in-vitro diagnosis of auto-immune and connective tissue diseases such as systemic lupus erythematosus (SLE) and Sjogren Syndrome.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K022800: Visiquant Anti-Nuclear Antibody Test System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K022800

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026